Know Cancer

forgot password

Effects of Soy Isoflavones on the Prostate, Breast and Bone

Phase 2
Not Enrolling
Breast Cancer, Prostate Cancer

Thank you

Trial Information

Effects of Soy Isoflavones on the Prostate, Breast and Bone

In the United States, consumption of soy products has dramatically increased in the past
several years. Foods made from soy are high in isoflavones and evidence suggests that these
isoflavones, genistein in particular, have many beneficial properties such as alleviating
menopausal side effects and reducing the risk of osteoporosis, breast cancer, and prostate
cancer. However, this data has been derived largely from studies with animal or cell models;
human trials are limited. This study will determine the effects of soy isoflavones on
quality of life and cancer and bone density markers.

While isoflavones have been purported to inhibit the proliferation of cancer cells, the
concentrations required for this anti-cancer effect were determined to be much higher than
the concentrations that can be achieved in plasma after intake of isoflavones. Recent animal
studies have suggested that isoflavones may be concentrated 10-fold in tissue compared to
blood concentrations. If this is true, then the higher concentration would be in the range
found in the cancer cell line research to be protective of cancer. This study will
determine whether tissue concentrations are similar to, higher than, or different than blood

This study will last 5 years and will comprise three populations: men with prostate cancer
on androgen ablation therapy, postmenopausal women on hormone replacement therapy (HRT), and
postmenopausal women not on HRT. Participants will be randomly assigned to receive either
isoflavone or placebo for two to four weeks. Participants' serum and serum extracts will be
incubated with cultured human cell lines (prostate cancer, breast cancer and osteoblasts)
and estrogenic and non-estrogenic mechanisms of action investigated. The human sera data
will be complemented by parallel studies of direct addition of crystalline isoflavones
(genistein, daidzein and equol) to the same cultured human cell lines. Participant's serum
and urine also will be tested for markers of bone resorption and formation. Quality of life
issues will be assessed with questionnaires.

Inclusion Criteria

Inclusion Criteria

- Scheduled for prostatectomy

- Willing and able to consume study tablets for at least 2 weeks prior to surgery

- Willing to accept random assignment

- Signed informed consent

Exclusion Criteria

- Unwilling to avoid soy intake during the study period

- Currently taking antibiotics

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Outcome Measure:

Markers of Bone Density

Principal Investigator

Christopher Gardner

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University


United States: Federal Government

Study ID:

R01 AT000486



Start Date:

May 2000

Completion Date:

January 2005

Related Keywords:

  • Breast Cancer
  • Prostate Cancer
  • isoflavones
  • soy
  • postmenopausal
  • men
  • prostate
  • breast
  • bone
  • Breast Neoplasms
  • Prostatic Neoplasms



Christopher Gardner Stanford, California  94305-5705